SCHEMBL2413883

SCHEMBL2413883

CC(=O)N1CC(CS(=O)(=O)c2nnnn2-c2ccccc2)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.52
MAPT P10636 8/20 0.52
LMNA P02545 7/20 0.48
HTT P42858 6/20 0.48
TP53 P04637 5/20 0.48
HPGD P15428 4/20 0.48
NPSR1 Q6W5P4 2/20 0.48
HSD17B10 Q99714 2/20 0.48
SMN1; SMN2 Q16637 5/20 0.43
GFER P55789 1/20 0.41
KMT2A Q03164 2/20 0.40
S1PR4 O95977 1/20 0.40
S1PR1 P21453 1/20 0.40
MAPK1 P28482 1/20 0.40
RAB9A P51151 1/20 0.40
POLB P06746 2/20 0.40
MEN1 O00255 1/20 0.40
PTPRB P23467 1/20 0.39
HSD11B1 P28845 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2414647 0.91 ALDH1A1 (0.48) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL2416198 0.88 ALDH1A1 (0.50) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL19433476 0.82 ALDH1A1 (0.62) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL18686925 0.80 ALDH1A1 (0.59) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL632936 0.79 GPR119 (0.47) ALDH1A1MAPTLMNATP53POLB
SCHEMBL13083703 0.79 ALDH1A1 (0.58) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL11895011 0.77 ALDH1A1 (0.53) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL11895013 0.77 ALDH1A1 (0.53) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL2415550 0.75 ALDH1A1 (0.53) ALDH1A1MAPTLMNAHTTTP53
SCHEMBL2978401 0.74 ALDH1A1 (0.71) ALDH1A1MAPTLMNAHTTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822503-B2 2-pyridone compounds TAISHO PHARMACEUTICAL CO., LTD (JP) 2014-09-02 US disclosed
US-8822503-B2 2-pyridone compounds TAISHO PHARMACEUTICAL CO., LTD (JP) 2014-09-02 US disclosed
US-8822503-B2 2-pyridone compounds TAISHO PHARMACEUTICAL CO., LTD (JP) 2014-09-02 US disclosed
EP-2508513-A1 2-PYRIDONE COMPOUNDS Taisho Pharmaceutical Co., Ltd. (JP) 2012-10-10 EP disclosed
EP-2508513-A1 2-PYRIDONE COMPOUNDS Taisho Pharmaceutical Co., Ltd. (JP) 2012-10-10 EP disclosed
US-20110237791-A1 2-PYRIDONE COMPOUNDS TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-09-29 US disclosed
US-20110237791-A1 2-PYRIDONE COMPOUNDS TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-09-29 US disclosed
US-20110237791-A1 2-PYRIDONE COMPOUNDS TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237791-A1 2-PYRIDONE COMPOUNDS PDXK, HK1, KCNJ2 ALDH1A1 2239/4885MAPT 532/4885LMNA 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.